- Services & Solutions
- Clients & Partners
Basic Cancer Research
SRI Biosciences is a leading provider of preclinical development services for oncology treatments. SRI's Center for Cancer and Metabolism partners with government agencies and pharmaceutical companies to
Identify molecular targets
Discover new drug candidates
Develop models for evaluating the efficacy of drugs
Elucidate drug mechanisms of action
Optimize promising drug candidates
Develop cost-effective strategies for synthesis
For the National Cancer Institute (NCI)—a client for more than 50 years—SRI provides preclinical cancer research, which includes evaluating the preclinical safety and pharmacokinetics of chemotherapeutics and chemopreventive agents. SRI also provides genetic toxicology testing for NCI's chemoprevention program, synthesizes compounds for NCI's carcinogen repository, and manufactures clinical trial materials.
SRI also operates one of seven National Cancer Institute (NCI) funded Tumor Glycome Laboratories. These laboratories are the principal component of the trans-NIH Alliance of Glycobiologists for Detection of Cancer and Cancer Risk, which is searching for glycan-based biomarkers for breast, ovarian, lung, prostate, and pancreatic cancers and melanoma. Learn more about SRI's Tumor Glycome Laboratory.
More than 30 years of research has led to numerous SRI drugs on the market or ready for licensing, including:
Targretin® (bexarotene), a retinoid receptor ligand marketed by Eisai
Tirapazamine, a hypoxic tissue-selective cytotoxin
TAS-108, a selective estrogen receptor modulator licensed to Taiho Pharmaceutical
PDX (pralatrexate), an antimetabolite licensed to Allos Therapeutics
SR16157, a dual estrone sulfatase / ER antagonist for breast cancer treatment
Learn more about SRI's research and services in these areas:
Using synthetic lethality to ID biomarkers for targeted anti-cancer drugs.
SRI’s Brown Laboratory is using selected peptides as “fishing hooks” to identify novel cell surface features.
SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.
SRI’s Brown Laboratory is utilizing cell-targeting peptides to deliver active therapeutic cargo to specific cells in vivo.